- Clinical Trials
- April 2025
- 60 Pages
Global
From €1435EUR$1,600USD£1,262GBP
€1794EUR$2,000USD£1,578GBP
- Drug Pipelines
- April 2025
- 180 Pages
Global
From €1794EUR$2,000USD£1,578GBP
€2243EUR$2,500USD£1,972GBP
- Report
- September 2025
- 150 Pages
Global
From €3454EUR$3,850USD£3,038GBP
- Report
- August 2025
- 152 Pages
Global
From €3544EUR$3,950USD£3,117GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2502EUR$2,789USD£2,201GBP
- Report
- June 2025
- 200 Pages
Global
From €2502EUR$2,789USD£2,201GBP
- Report
- October 2025
- 98 Pages
Global
From €3500EUR$4,179USD£3,186GBP
- Report
- December 2024
- 55 Pages
Global
From €2242EUR$2,499USD£1,972GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €1077EUR$1,200USD£947GBP
€1346EUR$1,500USD£1,183GBP
- Report
- February 2025
- 130 Pages
Global
From €3698EUR$4,123USD£3,253GBP
€4351EUR$4,850USD£3,827GBP
- Report
- June 2025
- 315 Pages
Africa
From €3095EUR$3,450USD£2,722GBP
- Report
- February 2020
- 360 Pages
Global
From €4395EUR$4,899USD£3,865GBP
- Report
- August 2019
- 488 Pages
Global
From €3588EUR$3,999USD£3,155GBP
- Report
- October 2021
- 145 Pages
Global
From €4305EUR$4,799USD£3,786GBP
- Report
- August 2024
- 660 Pages
Brazil
From €2368EUR$2,640USD£2,083GBP
€2960EUR$3,300USD£2,604GBP
- Report
- July 2024
- 500 Pages
Turkey
From €2368EUR$2,640USD£2,083GBP
€2960EUR$3,300USD£2,604GBP
- Report
- September 2022
- 300 Pages
China
From €2153EUR$2,400USD£1,894GBP
€2691EUR$3,000USD£2,367GBP
- Report
- June 2022
- 1500 Pages
Global
From €2799EUR$3,120USD£2,462GBP
€3499EUR$3,900USD£3,077GBP
- Report
- May 2022
- 240 Pages
Global
From €2368EUR$2,640USD£2,083GBP
€2960EUR$3,300USD£2,604GBP
- Report
- September 2024
- 120 Pages
China
From €5338EUR$5,950USD£4,695GBP
BeiGene is a market within the context of Oncology Drugs, which are drugs used to treat cancer. These drugs are used to target and destroy cancer cells, while minimizing damage to healthy cells. BeiGene is a biopharmaceutical company that develops and commercializes innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company focuses on developing therapies that target cancer cells with precision and accuracy, while also providing a safe and effective treatment for patients. BeiGene's portfolio includes a range of drugs, including small molecules, antibodies, and other biologics. The company also has a pipeline of novel therapies in development.
BeiGene is one of many companies in the Oncology Drugs market. Other companies include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
